Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.73 |
| ▸ | MMP9 | P14780 | 3/20 | 0.69 |
| ▸ | MMP3 | P08254 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | HBB | P68871 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | BACE1 | P56817 | 1/20 | 0.64 |
| ▸ | CBS | P35520 | 2/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ginkgetin SCHEMBL888410 | 0.89 | MAPT (0.86) | APPMMP9MMP3MAPTKDM4E | |
| Ginkgetin SCHEMBL31303838 | 0.89 | MAPT (0.86) | APPMMP9MMP3MAPTKDM4E | |
| Bilobetin SCHEMBL31094029 | 0.89 | MMP9 (0.80) | APPMMP9MMP3MAPTKDM4E | |
| Ginkgetin SCHEMBL30612275 | 0.89 | MAPT (0.86) | APPMMP9MMP3MAPTKDM4E | |
| Bilobetin SCHEMBL13485655 | 0.89 | MMP9 (0.80) | APPMMP9MMP3MAPTKDM4E | |
| SCHEMBL17166015 | 0.85 | MEN1 (0.74) | APPMMP9MMP3MAPTKDM4E | |
| Sciadopitisin SCHEMBL1158050 | 0.85 | MAPT (0.86) | APPMMP9MMP3MAPTKDM4E | |
| Sciadopitisin SCHEMBL30996894 | 0.85 | MAPT (0.86) | APPMMP9MMP3MAPTKDM4E | |
| Isoginkgetin SCHEMBL22459983 | 0.83 | MEN1 (0.80) | APPMMP9MMP3MAPTKDM4E | |
| Isoginkgetin SCHEMBL30293900 | 0.83 | MEN1 (0.80) | APPMMP9MMP3MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20240382448-A1 | METHODS FOR TREATING CORONAVIRUS INFECTION | BIOGENESYS, INC. | 2024-11-21 | — | — | US | disclosed |
| EP-4401711-A1 | STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401714-A1 | ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401712-A1 | ORAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4401713-A1 | ALIMENTARY-RELATED PARTICLES, PRODUCTION METHODS, AND PRODUCTION APPARATUS | Nulixir Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240165036-A1 | ENCAPSULATED VITAMIN D | Nulixir Inc. | 2024-05-23 | — | — | US | disclosed |
| US-20230404126-A1 | ENCAPSULATED PRECURSORS OF NICOTINAMIDE ADENINE DINUCLEOTIDE AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-12-21 | — | — | US | disclosed |
| WO-2023043854-A1 | ALIMENTARY-RELATED PARTICLES, PRODUCTION METHODS, AND PRODUCTION APPARATUS | Nulixir Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023043853-A1 | ORAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023043852-A1 | STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023043855-A1 | ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-20230079480-A1 | STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-03-16 | — | — | US | disclosed |
| US-20230082651-A1 | STABLE AQUEOUS COMPOSITIONS OF PLANTS EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-03-16 | — | — | US | disclosed |
| US-20230081296-A1 | STABLE NON-AQUEOUS COMPOSITIONS OF PLANTS EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-03-16 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| WO-2023287620-A1 | METHODS FOR TREATING CORONAVIRUS INFECTION | RABINOFF MICHAEL (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | APP 3074/4885MMP9 625/4885MMP3 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.